Efficacy and factors associated with reactivation following intravitreal ranibizumab or conbercept for retinopathy of prematurity
Ranibizumab and conbercept are effective for treating ROP. A lower PMA at initial treatment and Zone I ROP were identified as significant risk factors for reactivation. Infants with these characteristics require closer and more prolonged follow-up after anti-VEGF therapy.
Authors
- J. Li
- Jiafen Liu (ORCID: https://orcid.org/0000-0002-6599-2237)
- Huanhuan Zhao (ORCID: https://orcid.org/0000-0002-5274-5595)
- Ge Mu
- Qiuhui Liu
- Suzhen Xie
- Xuelin Huang
- Jiao Zheng
- Jianxun Wang
Institutions
- Guangdong Province Women and Children Hospital (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2026-02-19
- DOI
- https://doi.org/10.3389/fmed.2026.1754490
- Primary Topic
- Retinopathy of Prematurity Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00